Full Text:   <117>

Summary:  <40>

Suppl. Mater.: 

CLC number: R457.1

On-line Access: 2020-12-09

Received: 2020-09-25

Revision Accepted: 2020-10-22

Crosschecked: 2020-11-11

Cited: 0

Clicked: 247

Citations:  Bibtex RefMan EndNote GB/T7714

 ORCID:

Wei-ling Xiang

https://orcid.org/0000-0001-5365-3951

-   Go to

Article info.
Open peer comments

Journal of Zhejiang University SCIENCE B 2020 Vol.21 No.12 P.955-960

http://doi.org/10.1631/jzus.B2000593


Clinical characteristics and plasma antibody titer of patients with COVID-19 in Zhejiang, China


Author(s):  Wei-ling Xiang, Jing-jing Cheng, Lian-peng Wu, Bing-yu Chen, Wen-xin Li, Dan-ying Qiu, Wei Zhang, Fei-hang Ge, Dong Chen, Zhen Wang

Affiliation(s):  Research Center of Blood Transfusion Medicine, Ministry of Education Key Laboratory of Laboratory Medicine, Department of Blood Transfusion, Zhejiang Provincial People’s Hospital, People’s Hospital of Hangzhou Medical College, Hangzhou 310014, China; more

Corresponding email(s):   chendong_wz@126.com, wangzhen@hmc.edu.cn

Key Words:  Coronavirus disease 2019 (COVID-19), Convalescent plasma, Clinical characteristics, Antibody titer


Wei-ling Xiang, Jing-jing Cheng, Lian-peng Wu, Bing-yu Chen, Wen-xin Li, Dan-ying Qiu, Wei Zhang, Fei-hang Ge, Dong Chen, Zhen Wang. Clinical characteristics and plasma antibody titer of patients with COVID-19 in Zhejiang, China[J]. Journal of Zhejiang University Science B, 2020, 21(12): 955-960.

@article{title="Clinical characteristics and plasma antibody titer of patients with COVID-19 in Zhejiang, China",
author="Wei-ling Xiang, Jing-jing Cheng, Lian-peng Wu, Bing-yu Chen, Wen-xin Li, Dan-ying Qiu, Wei Zhang, Fei-hang Ge, Dong Chen, Zhen Wang",
journal="Journal of Zhejiang University Science B",
volume="21",
number="12",
pages="955-960",
year="2020",
publisher="Zhejiang University Press & Springer",
doi="10.1631/jzus.B2000593"
}

%0 Journal Article
%T Clinical characteristics and plasma antibody titer of patients with COVID-19 in Zhejiang, China
%A Wei-ling Xiang
%A Jing-jing Cheng
%A Lian-peng Wu
%A Bing-yu Chen
%A Wen-xin Li
%A Dan-ying Qiu
%A Wei Zhang
%A Fei-hang Ge
%A Dong Chen
%A Zhen Wang
%J Journal of Zhejiang University SCIENCE B
%V 21
%N 12
%P 955-960
%@ 1673-1581
%D 2020
%I Zhejiang University Press & Springer
%DOI 10.1631/jzus.B2000593

TY - JOUR
T1 - Clinical characteristics and plasma antibody titer of patients with COVID-19 in Zhejiang, China
A1 - Wei-ling Xiang
A1 - Jing-jing Cheng
A1 - Lian-peng Wu
A1 - Bing-yu Chen
A1 - Wen-xin Li
A1 - Dan-ying Qiu
A1 - Wei Zhang
A1 - Fei-hang Ge
A1 - Dong Chen
A1 - Zhen Wang
J0 - Journal of Zhejiang University Science B
VL - 21
IS - 12
SP - 955
EP - 960
%@ 1673-1581
Y1 - 2020
PB - Zhejiang University Press & Springer
ER -
DOI - 10.1631/jzus.B2000593


Abstract: 
coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which first affected humans in China on December 31, 2019 (Shi et al., 2020). Coronaviruses generally cause mild, self-limiting upper respiratory tract infections in humans, such as the common cold, pneumonia, and gastroenteritis (To et al., 2013; Berry et al., 2015; Chan et al., 2015). According to the Report of the World Health Organization (WHO)-China Joint Mission on COVID-19 (WHO, 2020), the case fatality rate of COVID-19 increases with age, while the rate among males is higher than that among females (4.7% and 2.8%, respectively). Since an effective vaccine and specific anti-viral drugs are still under development, passive immunization using the convalescent plasma (CP) of recovered COVID-19 donors may offer a suitable therapeutic strategy for severely ill patients in the meantime. So far, several studies have shown therapeutic efficacy of CP transfusion in treating COVID-19 cases. A pilot study first reported that transfusion of CP with neutralizing antibody titers above 1:640 was well tolerated and could potentially improve clinical outcomes through neutralizing viremia in severe COVID-19 cases (Chen et al., 2020). Immunoglobulin G (IgG) and IgM are the most abundant and important antibodies in protecting the human body from viral attack (Arabi et al., 2015; Marano et al., 2016). Our study aimed to understand the aspects of plasma antibody titer levels in convalescent patients, as well as assessing the clinical characteristics of normal, severely ill, and critically ill patients, and thus provide a basis for guiding CP therapy. We also hoped to find indicators which could serve as a reference in predicting the progression of the disease.

浙江省新冠病毒肺炎患者的临床特征和血浆抗体滴度的调查与分析

目的:利用胶体金快速检测试剂盒测定恢复期患者血浆中IgG/IgM的抗体滴度,回顾性分析新型冠状病毒肺炎(COVID-19)患者临床特征、抗体效价变化特点,以及两者间的相关性.
创新点:利用胶体金检测试剂盒检测恢复期血浆抗体滴度,结合重症及危重症患者病例特点及实验室检测指标分析血浆抗体效价变化规律,及其临床特征的关系,为临床重症及危重症患者诊治以及筛选恢复期血浆供者提供参考依据.
方法:收集293份来自COVID-19康复者随访过程中的血液标本,取血浆原液,用生理盐水按不同比例(1:80、1:160、1:320和1:640)稀释后进行胶体金试纸法IgG/IgM抗体检测,并记录相应患者检验指标水平.通过电子病历系统检索回顾性分析温州市第六人民医院截至2020年2月24日确诊的COVID-19患者的流行病学特征和临床信息.通过线性回归分析两变量之间的相关性,P<0.05时具有统计学意义.
结论:症状出现4~6周时,COVID-19患者恢复期血浆IgG滴度水平可达到1:320~1:640或者更高水平.此时部分患者的血浆IgM仍为阳性.COVID-19患者恢复期血浆IgM抗体滴度检测结果显示男性较女性高.本研究中危重症患者均需要无创通气来维持生命,且重症和极危重症患者均易发生水、电解质紊乱.COVID-19发病早期发生凝血功能障碍及炎症,与恢复期血浆中IgG和IgM的抗体滴度水平存在一定相关性.

关键词:新型冠状病毒肺炎(COVID-19);恢复期血浆;临床特征;抗体滴度

Darkslateblue:Affiliate; Royal Blue:Author; Turquoise:Article

Reference

[1]Arabi Y, Balkhy H, Hajeer AH, et al., 2015. Feasibility, safety, clinical, and laboratory effects of convalescent plasma therapy for patients with Middle East respiratory syndrome coronavirus infection: a study protocol. SpringerPlus, 4:709.

[2]Berry M, Gamieldien J, Fielding BC, 2015. Identification of new respiratory viruses in the new millennium. Viruses, 7(3):996-1019.

[3]Chan JFW, Yao YF, Yeung ML, et al., 2015. Treatment with lopinavir/ritonavir or interferon-β1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset. J Infect Dis, 212(12):1904-1913.

[4]Chen L, Xiong J, Bao L, et al., 2020. Convalescent plasma as a potential therapy for COVID-19. Lancet Infect Dis, 20(4):398-400.

[5]Huang DQ, Chen R, Wang YQ, et al., 2019. Development of a colloidal gold-based immunochromatographic strip for rapid detection of Rice stripe virus. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 20(4):343-354.

[6]Lee YL, Liao CH, Liu PY, et al., 2020. Dynamics of anti-SARS-CoV-2 IgM and IgG antibodies among COVID-19 patients. J Infect, 81(2):E55-E58.

[7]Li L, Tong XL, Chen HW, et al., 2020. Characteristics and serological patterns of COVID-19 convalescent plasma donors: optimal donors and timing of donation. Transfusion, 60(8):1765-1772.

[8]Liu YL, Sun WW, Li J, et al., 2020. Clinical features and progression of acute respiratory distress syndrome in coronavirus disease 2019. medRxiv, preprint.

[9]Long QX, Liu BZ, Deng HJ, et al., 2020. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med, 26(6):845-848.

[10]Marano G, Vaglio S, Pupella S, et al., 2016. Convalescent plasma: new evidence for an old therapeutic tool? Blood Transfus, 14(2):152-157.

[11]Samanta D, Willis E, 2016. Focal seizure associated with human parvovirus B19 infection in a non-encephalopathic child. World J Pediatr, 12(1):118-120.

[12]Shi Y, Wang G, Cai XP, et al., 2020. An overview of COVID-19. J Zhejiang Univ Sci B (Biomed & Biotechnol), 21(5):343-360.

[13]Singh L, Mishra S, Prasanna S, et al., 2015. Seroprevalence of TORCH infections in antenatal and HIV positive patient populations. Med J Armed Forces India, 71(2):135-138.

[14]To KKW, Hung IFN, Chan JFW, et al., 2013. From SARS coronavirus to novel animal and human coronaviruses. J Thorac Dis, 5(S2):S103-S108.

[15]WHO, 2020. Report of the WHO-China Joint Mission on coronavirus disease 2019 (COVID-19). https://www.who. int/publications/i/item/report-of-the-who-china-joint-mission-on-coronavirus-disease-2019-(covid-19)

[16]Zhang LB, Pang RR, Xue X, et al., 2020. Anti-SARS-CoV-2 virus antibody levels in convalescent plasma of six donors who have recovered from COVID-19. Aging, 12(8):6536-6542.

[17]https://doi.org/10.18632/aging.103102

[18]List of electronic supplementary materials

[19]Fig. S1 Correlation between IgG/IgM titer and different laboratory indexes

Open peer comments: Debate/Discuss/Question/Opinion

<1>

Please provide your name, email address and a comment





Journal of Zhejiang University-SCIENCE, 38 Zheda Road, Hangzhou 310027, China
Tel: +86-571-87952783; E-mail: cjzhang@zju.edu.cn
Copyright © 2000 - Journal of Zhejiang University-SCIENCE